Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs

PartnershipPositive

AI Analysis

Summary

Zealand Pharma entered into a partnership with Generate:Biomedicines valued up to $1.2B to leverage AI-designed generative platform for developing multispecific drug candidates in obesity and metabolic disorders.

Importance:7/10

Sentiment:

0.60

partnershipAI platformobesitymetabolic diseasedrug developmentmultispecific drugs

Related Companies

$ZEAL

Read the original article

Published by BioSpace on October 14, 2026 1:11 PM

Read Original